乳腺癌患者接受或不接受内乳照射的结局:单中心回顾性倾向评分匹配研究
该单中心回顾性队列研究纳入2012年1月至2018年12月570例淋巴结阳性乳腺癌患者,比较接受内乳放疗(IMN-RT,143例)与未覆盖内乳(non-IMN-RT,427例)患者的4年无远处转移生存(DMFS)。倾向评分匹配后每组139例,中位随访4.3年,两组4年DMFS、总生存、无病生存及心脏毒性均无显著差异。作者结论为在现代放疗技术时代的真实世界数据中未发现内乳照射的获益。
要点
- 倾向评分匹配后每组139例,中位随访4.3年。
- 4年DMFS:IMN-RT组79.1% vs non-IMN-RT组82.8%(P = .43)。
- 4年总生存、无病生存及心脏毒性两组均无显著差异。
核心结论
- 在现代放疗技术时代的真实世界数据中,作者未能发现内乳照射的获益。
研究设计与样本
- 单中心回顾性队列研究,2012年1月至2018年12月共评估570例淋巴结阳性乳腺癌患者,分为IMN-RT组143例与non-IMN-RT组427例,倾向评分匹配后每组139例。
主要发现
- 4年DMFS:IMN-RT组79.1%(95%CI 70.1%-85.6%)vs non-IMN-RT组82.8%(95%CI 74.2%-88.7%),P = .43。
- 4年总生存:IMN-RT组84.3%(95%CI 76.4%-89.8%)vs non-IMN-RT组88.1%(95%CI 81.0%-92.7%),P = .39。
- 4年无病生存:IMN-RT组77.1%(95%CI 68.1%-83.8%)vs non-IMN-RT组82.1%(95%CI 73.6%-88.1%),P = .29。
- 心脏毒性:IMN-RT组1.4% vs non-IMN-RT组1.4%,P = 1.0,无显著差异。
关键数值与推荐
- IMN-RT组的定义为处方剂量的80%覆盖≥98%的内乳临床靶区。
- 主要结局为4年DMFS,次要结局为4年总生存、4年无病生存和心脏毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Internal mammary lymph node radiation therapy (IMN-RT) has unclear benefits. Historical data were based on only conventional (2-dimensional) radiation techniques. In this 3-dimensional radiation therapy era, we compared the distant metastasis-free survival (DMFS) rates of patients receiving IMN-RT with those who did not include coverage of the IMN (non-IMN-RT). This study aimed to determine the relationship between IMN-RT and distant metastasis control in patients with lymph node-positive breast cancer. METHODS AND MATERIALS: This was a single-center retrospective cohort study. Patients were divided into 2 groups: IMN-RT and non-IMN-RT. The criterion of the IMN-RT group was that 80% of the prescribed dose covered ≥98% of the Clinical Target Volume of IMN. The primary outcome was 4-year DMFS, and the secondary outcomes were 4-year overall survival, 4-year disease-free survival, and cardiac toxicity. RESULTS: From January 2012 to December 2018, 570 patients were evaluated (IMN-RT, 143 patients; non-IMN-RT, 427 patients). Propensity score matching decreased the number of patients in each group to 139. The median follow-up was 4.3 years. The 4-year DMFS rates were as follows: IMN-RT, 79.1% (95% confidence interval [CI], 70.1%-85.6%), and non-IMN-RT, 82.8% (95% CI, 74.2%-88.7%; P = .43). The groups' 4-year overall survival and disease-free survival rates did not differ. The 4-year overall survival rates were 84.3% (95% CI, 76.4%-89.8%) for IMN-RT and 88.1% (95% CI, 81.0%-92.7%; P = .39) for non-IMN-RT. The 4-year disease-free survival rates were 77.1% (95% CI, 68.1%-83.8%) for IMN-RT and 82.1% (95% CI, 73.6%-88.1%; P = .29) for non-IMN-RT. There was no significant difference in cardiac toxicity (IMN-RT, 1.4%; non-IMN-RT, 1.4%; P = 1.0). CONCLUSIONS: In the modern radiation technique era with real-world data, we could not find a benefit of internal mammary irradiation.
引用
- Jitwatcharakomol T, Setakoranukul J, Ithimakin S, et al. Outcomes of Patients With Breast Cancer Treated With or Without Internal Mammary Irradiation: A Single-Center, Retrospective Propensity Score-Matched Study. Adv Radiat Oncol. 2022. PMID: 36483062. doi:10.1016/j.adro.2022.101072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。